Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of APX001 for candidemia with or without invasive candidiasis in non-neutropenic adults
MOH_2018-05-15_002379Phase 2Not yet recruiting
- Sponsor
- Amplyx Pharmaceuticals
- Start
- Apr 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fosmanogepix in candidemia and invasive candidiasis, sponsored by Amplyx Pharmaceuticals. Primary endpoints: Efficacy of APX001 in candidemia, Safety of APX001 and 1 more. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
fosmanogepix
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on MOH_2018-05-15_002379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-15_002379.